Results 141 to 150 of about 1,413,284 (292)
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
Background In children born at high altitude, lung development is affected by hypoxia, which can lead to pulmonary hypertension and right ventricular failure.
Luca Zazzeron +10 more
doaj +1 more source
Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients
Abbreviated versions of the risk stratification strategy of the European Society of Cardiology (ESC)/European Respiratory Society (ERS) pulmonary hypertension guidelines have been recently validated in patients with pulmonary arterial hypertension.
Grünig, Ekkehard +18 more
core +1 more source
Macrophage‐derived S100 calcium‐binding protein A9 (S100A9) promotes the pathological progression of pulmonary arterial hypertension (PAH). S100A9 upregulates the interaction between signal‐transducing adaptor protein 2 and leucine‐rich repeat kinase 2, thereby regulating mitochondria–endoplasmic reticulum (ER) contact.
Chen Gong +15 more
wiley +1 more source
Data on demographic characteristics and therapeutic approaches in Latin American pulmonary arterial hypertension (PAH) patients are scarce. Pulmonary Hypertension Mexican registry (REMEHIP) is a multicenter Mexican registry of adult and pediatric ...
Carlos Jerjes‐Sánchez +12 more
doaj +1 more source
Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
In order to provide an overview of current knowledge, the literature was systematically examined for clinical studies, which evaluate the safety and effectiveness of bosentan in pediatric pulmonary arterial hypertension (PAH).3 databases (MEDLINE, EMBASE and BIOSIS) were searched for the period January 2000 - October 2007 using the key words 'pulmonary
openaire +4 more sources
Current Management of pulmonary Hypertension
treatment of pulmonary hypertension. New methods of the new drugs.
Jezawi, Abdullah
core
Background: Combined angiotensin II receptor antagonism and neprilysin inhibition by LCZ696 reduces morbidity and mortality in heart failure patients and works by reducing RAAS activity and increasing cGMP levels.
Nyengaard, Jens Randel +8 more
core +1 more source
We detect the risk factors and image characteristics of incidentally detected IAAD. Independent risk factors of IAAD included fatty liver and smoking. In the ultrasound findings of IAAD, an intimal flap was frequently observed. In the CT scan, displacement of intimal calcifications was frequently observed. For suspected IAAD, the abdominal aorta should
Hiromasa Tsubouchi +15 more
wiley +1 more source
Pulmonary vasodilator treatment can improve hemodynamics, right ventricular function, symptoms, and survival in pediatric pulmonary hypertension (PH). However, clinical trial data are lacking due to many constraints.
Catherine M. Avitabile +18 more
doaj +1 more source

